FOLH1 and prostate carcinoma: PSMA has especially been targeted in prostate cancer patients, with various ongoing clinical trials (NCT01140373 (99, 100), NCT01929239, NCT00664196; and NCT03089203) (see Tregs and Table 10) (101).